Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

Embodiments are directed to secnidazole formulations and the use of a secnidazole formulation for the treatment of trichomoniasis in a subject in need thereof.

The present invention provides taste masked formulations of phenylbutyrate and methods of use in treatment nitrogen retention and other disorders. Formulations of the invention also reduced CNS adverse events and allow for longer consumption times.

The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation.

An orally disintegrating composition having a bimodal particle size distribution, methods for its production and use thereof are provided.

Chitosan can be coated, e.g., in 0.06 or 0.6 wt. %, over spherical silica, e.g., HYPS, loaded with spinel ferrites of theoretical formula MFe.sub.2O.sub.4, wherein M is Ni, Cu, Co, and/or Mn, e.g., at 30 wt. %, and cisplatin. Chitosan can be fabricated over Pt or cisplatin) bound CuFe.sub.2O.sub.4-HYPS and CuFe.sub.2O.sub.4-HYPS followed by Pt loading. Cisplatin and Pt—CuFe.sub.2O.sub.4-HYPS-chitosan at 0.025 to 0.5 mg/mL exhibit cytotoxicity against human breast cancer cell line (MCF-7) and human embryonic kidney cells (HEK293), relative to Pt—CuFe.sub.2O.sub.4-HYPS, with Pt—CuFe.sub.2O.sub.4-HYPS-chitosan, showing non-significant anti-cancer effects due to mediated Pt release. Pt—CuFe.sub.2O.sub.4/HYPS and CuFe.sub.2O.sub.4-HYPS-chitosan-Pt reduced cell viability using a different dose effect. Cisplatin in certain composites was less cytotoxic to HEK293 than MCF7, making the a targeted drug delivery system. Inventive composites may improve multifunctional theranostic applications involving pH stimuli, temperature-based drug release, and diagnosis based treatment such as hyperthermia.

A particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%, and a process for preparation of the hollow particle, which includes granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer.

A composition including metallic silver nanoparticles is supported on a carrier, wherein the carrier is in the form of particles. The carrier is selected from an inert carrier or an antibiotic. The composition further includes at least one antibiotic in the case the carrier is an inert carrier. A related nanosystem includes a composition having metallic silver nanoparticles or a mixture of silver nanoparticles and at least one antibiotic for use in the treatment of an infection caused by at least one strain of bacteria resistant to at least one antibiotic. Pharmaceutical compositions and methods for the preparation of these compositions and nanosystems are also used for the treatment of bacterial infections.

Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.